Citations

Clear

2 citation(s) found for "Seyedin, Steven".

The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis
Yeakel, John , Seyedin, Steven N. , Harada, Garrett K. , Hagopian, Garo, Mahmood, Sharmeen, Harris, Jeremy P. , Abbott, Elliot M. , Lindner, Sydney, Dayyani, Farshid , Sehgal, Varun , Kuo, Jeffrey V., Abi‐Jaoudeh, Nadine , Harada, Garrett , Dayyani, Farshid , Abi-Jaoudeh, Nadine , Mahmood, Sharmeen, Bennett, Rebecca

Mayo Clinic

Cancers | July 1, 2024 | Volume: 16 | Issue: 13 | Pages: 2401

10.3390/cancers16132401 | PMID 39001464 Get It

Y-90 Selective Internal Radiotherapy (SIRT) is an ablative therapy used for inoperable liver metastasis. The purpose of this investigation was to examine the impact of local control after SIRT on overall survival (OS) in oligometastatic patients. A retrospective, single-institution study identified oligometastatic patients with ≤5 non-intracranial metastases receiving unilateral or bilateral lobar Y-90 SIRT from 2009 to 2021. The primary endpoint was OS defined from Y-90 SIRT completion to the date of death or last follow-up. Local failure was classified as a progressive disease at the target lesion(s) by RECIST v1.1 criteria starting at 3 months after SIRT. With a median follow-up of 15.7 months, 33 patients were identified who had a total of 79 oligometastatic lesions treated with SIRT, with the majority histology of colorectal adenocarcinoma (n = 22). In total, 94% of patients completed the Y-90 lobectomy. Of the 79 individual lesions treated, 22 (27.8%) failed. Thirteen patients received salvage liver-directed therapy following intrahepatic failure; ten received repeat SIRT. Median OS (mOS) was 20.1 months, and 12-month OS was 68.2%. Intralesional failure was associated with worse 1 y OS (52.3% vs. 86.2%, p = 0.004). These results suggest that intralesional failure following Y-90 may be associated with inferior OS, emphasizing the importance of disease control in low-metastatic-burden patients.
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Flaig, Thomas W. , Abern, Michael, Bangs, Rick , Begovic, Jovan, Brown, Jason, Buyyounouski, Mark K. , Chan, Kevin, Chang, Paul, Chin, Arnold I., Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kaimakliotis, Hristos, Kundu, Shilajit, Lele, Subodh M. , Luckenbaugh, Amy, Maldonado, Jonathan, Mei, Lin, Montgomery, Jeffrey S., Parikh, Mamta, Patterson, Anthony, Peyton, Charles, Preston, Mark A. , Richards, Kyle, Seyedin, Steven, Stewart, Tyler, Sundi, Debasish, Swami, Umang, Tollefson, Matthew, Wright, Jonathan L. , Cassara, Carly J., Sliker, Bailee, Inman, Brant A. , Friedlander, Terence W. , Pagliaro, Lance C. , Inman, Brant A , Spiess, Philippe E. , Abern, Michael, Begovic, Jovan, Brown, Jason, Chan, Kevin, Chang, Paul, Chin, Arnold I., Kaimakliotis, Hristos, Kundu, Shilajit, Luckenbaugh, Amy, Maldonado, Jonathan, Mei, Lin, Parikh, Mamta, Peyton, Charles, Plimack, Elizabeth R. , Richards, Kyle, Seyedin, Steven, Siefker-Radtke, Arlene Odelia , Stewart, Tyler, Sundi, Debasish, Swami, Umang, Tollefson, Matthew, Cassara, Carly J., Sliker, Bailee

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 329-354

10.6004/jnccn.2020.0011 | PMID 32135513 Get It

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org . Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.